ProMetic Life Sciences Inc. (TSE:PLI)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Royal Bank Of Canada in a note issued to investors on Thursday, StockTargetPrices.com reports.
PLI has been the topic of several other reports. TD Securities reissued a “speculative buy” rating and issued a C$4.50 target price on shares of ProMetic Life Sciences in a research report on Wednesday, September 28th. Scotiabank reissued an “outperform” rating and issued a C$5.00 target price on shares of ProMetic Life Sciences in a research report on Thursday, August 25th. Finally, CIBC dropped their target price on shares of ProMetic Life Sciences from C$5.00 to C$4.85 in a research report on Thursday, August 25th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of C$4.84.
Shares of ProMetic Life Sciences (TSE:PLI) traded down 1.89% during trading on Thursday, hitting $3.11. 520,719 shares of the stock were exchanged. The stock’s 50 day moving average is $2.92 and its 200-day moving average is $3.01. The stock’s market cap is $1.88 billion. ProMetic Life Sciences has a 12-month low of $1.67 and a 12-month high of $3.62.
ProMetic Life Sciences Company Profile